Halozyme Therapeutics, Inc. (HALO) Stock Price & News

Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia

About Halozyme Therapeutics, Inc.

CEOHelen I. Torley

Employees423

Founded1998

HeadquartersСан-Диего, Калифорни, Америкийн Нэгдсэн Улс

Sector-

Websitehalozyme.com

All values in USD	2025 оны 9-р сар	2025 оны 12-р сар	2026 оны 3-р сар	2026 оны 6-р сар
Revenue	354.26 сая	451.77 сая	376.71 сая	481.00 сая
Cost of goods sold	72.49 сая	110.67 сая	104.80 сая	106.84 сая
Cost of revenue	72.49 сая	110.67 сая	104.80 сая	106.84 сая
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	46.09 сая	63.33 сая	57.88 сая	57.00 сая
Operating expense	63.85 сая	86.70 сая	87.39 сая	86.51 сая
Total operating expenses	136.34 сая	197.37 сая	192.19 сая	193.34 сая
Operating income	217.92 сая	254.40 сая	184.52 сая	287.65 сая
Other non operating income	-	-	-	-
EBT including unusual items	218.96 сая	-100.85 сая	180.33 сая	284.90 сая
EBT excluding unusual items	218.96 сая	251.58 сая	180.30 сая	284.90 сая
Income tax expense	43.73 сая	40.74 сая	30.28 сая	54.99 сая
Effective tax rate	19.97%	-40.40%	16.79%	19.30%
Other operating expenses	-	-	-	-
Net income	175.22 сая	-141.59 сая	150.05 сая	229.91 сая
Net profit margin	49.46%	-31.34%	39.83%	47.80%
Earnings per share	1.72	-0.24	1.60	2.28
Interest and investment income	5.33 сая	2.09 сая	1.29 сая	2.84 сая
Interest expense	-4.30 сая	-4.91 сая	-5.51 сая	-5.59 сая
Net interest expenses	1.04 сая	-2.82 сая	-4.22 сая	-2.75 сая
Depreciation and amortization charges	-	-	-	-
EBITDA	236.84 сая	279.08 сая	215.65 сая	319.12 сая
Gain or loss from assets sale	-	2.62 сая	-	76.00 мян

Ask anything